Lifeboat Foundation

Existing electronic skin (e-skin) sensing platforms are equipped to monitor physical parameters using power from batteries or near-field communication. For e-skins to be applied in the next generation of robotics and medical devices, they must operate wirelessly and be self-powered. However, despite recent efforts to harvest energy from the human body, self-powered e-skin with the ability to perform biosensing with Bluetooth communication are limited because of the lack of a continuous energy source and limited power efficiency. Here, we report a flexible and fully perspiration-powered integrated electronic skin (PPES) for multiplexed metabolic sensing in situ. The battery-free e-skin contains multimodal sensors and highly efficient lactate biofuel cells that use a unique integration of zero- to three-dimensional nanomaterials to achieve high power intensity and long-term stability. The PPES delivered a record-breaking power density of 3.5 milliwatt·centimeter⁻² for biofuel cells in untreated human body fluids (human sweat) and displayed a very stable performance during a 60-hour continuous operation. It selectively monitored key metabolic analytes (e.g., urea, NH₄⁺, glucose, and pH) and the skin temperature during prolonged physical activities and wirelessly transmitted the data to the user interface using Bluetooth. The PPES was also able to monitor muscle contraction and work as a human-machine interface for human-prosthesis walking.

Recent advances in robotics have enabled soft electronic devices at different scales with excellent biocompatibility and mechanical properties; these advances have rendered novel robotic functionalities suitable for various medical applications, such as diagnosis and drug delivery, soft surgery tools, human-machine interaction (HMI), wearable computing, health monitoring, assistive robotics, and prosthesis (1–6). Electronic skin (e-skin) can have similar characteristics to human skin, such as mechanical durability and stretchability and the ability to measure various sensations such as temperature and pressure (7–11). Moreover, e-skin can be augmented with capabilities beyond those of the normal human skin by incorporating advanced bioelectronics materials and devices.

The global coronavirus death toll surpassed 200,000 on Saturday, according to John Hopkins University data.

The grim total was reached a day after presidents and prime ministers agreed to work together to develop new vaccines, tests and treatments at a virtual meeting with both the World Health Organization (WHO) and Bill & Melinda Gates Foundation.

“We will only halt COVID-19 through solidarity,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “Countries, health partners, manufacturers, and the private sector must act together and ensure that the fruits of science and research can benefit everybody.”

North Korean dictator Kim Jong Un is in a “vegetative state” after he underwent heart surgery earlier this month, a Japanese magazine says.

The weekly Shukan Gendai reported Friday that a Chinese medic sent to North Korea as part of a team to treat Kim believed a delay in a simple procedure left the leader severely ill, Reuters reported.

North Korean media hasn’t mentioned Kim’s health or whereabouts, even though reports by other media have sparked international speculation about his well-being.

Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease. However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients. Methods Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay. Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2. The levels and the time course of SARS-CoV-2-specific NAbs and the spike-binding antibodies were monitored at the same time.

Have a good day group 😅.

On Thursday, Donald Trump raised a few eyebrows as he spoke at the White House daily briefing on the coronavirus. Like us previously He reportedly suggested using UV lights or injecting disinfectants into a person affected by the virus.

Oddly enough, Trump’s suggestion not only sparked a conversation, as many people ignored him, but also prompted RB, the makers of Lysol and Dettol, to release a statement to assure everyone that their products are NOT for internal use, despite Trump’s suggestion.

Continue reading “The manufacturer of Lysol issues a warning against the use of its disinfectant products for internal use after Donald Trump’s comments on a possible treatment for patients with coronavirus” »

This case series describes clinical characteristics, health services use, and outcomes of patients with confirmed coronavirus disease 2019 (COVID-19) cared for at 12 hospitals of a single health system in the New York City (NYC) area.

In the constant battle against the spread of infectious diseases, scientists are continually on the hunt for new weapons that specifically target pathogenic microbes. Now, investigators from the Center for Radiological Research at Columbia University Irving Medical Center (CUIMC) believe they may have found a new, low-cost solution to eradicating airborne viruses in indoor public spaces. The research team found that continuous low doses of far ultraviolet C (far-UVC) light can kill airborne flu viruses without harming human tissues. The findings from the new study—published today in Scientific Reports in an article entitled “Far-UVC Light: A New Tool to Control the Spread of Airborne-Mediated Microbial Diseases”—suggests that use of overhead far-UVC light in hospitals, doctors’ offices, schools, airports, airplanes, and other public spaces could provide a powerful check on seasonal influenza epidemics, as well as influenza pandemics.

Scientists have known for decades that broad-spectrum UVC light, which has a wavelength of between 200 to 400 nanometers (nm), is highly effective at killing bacteria and viruses by destroying the molecular bonds that hold their DNA together. This conventional UV light is routinely used to decontaminate surgical equipment.

“Unfortunately, conventional germicidal UV light is also a human health hazard and can lead to skin cancer and cataracts, which prevents its use in public spaces,” explained senior study investigator David Brenner, Ph.D., director of the Center for Radiological Research and professor at CUIMC.

April 2020

The COVID-19 pandemic caused by SARS-CoV-2 has brought about an unprecedented crisis, taking a heavy toll on human health, lives as well as the global economy. There are no SARS-CoV-2-specific treatments or vaccines available due to the novelty of this virus. Hence, rapid development of effective vaccines against SARS-CoV-2 is urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies potently neutralized 10 representative SARS-CoV-2 strains, indicative of a possible broader neutralizing ability against SARS-CoV-2 strains circulating worldwide. Immunization with two different doses (3μg or 6 μg per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without any antibody-dependent enhancement of infection. Systematic evaluation of PiCoVacc via monitoring clinical signs, hematological and biochemical index, and histophathological analysis in macaques suggests that it is safe. These data support the rapid clinical development of SARS-CoV-2 vaccines for humans.

One Sentence Summary A purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc) confers complete protection in non-human primates against SARS-CoV-2 strains circulating worldwide by eliciting potent humoral responses devoid of immunopathology.

The authors have declared no competing interest.

On March 16, Moderna and the National Institute of Allergy & Infectious Diseases (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.

Without placing too much significance on this, it is a good sign, suggesting that the trial is progressing well and there are no obvious bad side effects from the first round.

Lisa Jackson, senior investigator, Kaiser Permanente Washington Health Research Institute, who is heading the study, told USA Today that the physicians at Kaiser Permanente’s Vaccine Treatment and Evaluation Unit in Seattle don’t have results from the first round. This suggests that the study data is blinded, meaning it will not be released until a specific point in the trial.